<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717414</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-536-MF-002</org_study_id>
    <secondary_id>2020-000607-36</secondary_id>
    <secondary_id>U1111-1260-9595</secondary_id>
    <nct_id>NCT04717414</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions</brief_title>
  <acronym>INDEPENDENCE</acronym>
  <official_title>A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept&#xD;
      compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated&#xD;
      Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who&#xD;
      require red blood cell count (RBC) transfusions.&#xD;
&#xD;
      The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core&#xD;
      Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an&#xD;
      Open-label Extension Treatment Period), and a Posttreatment Follow-up Period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Permitted Concomitant Medications and Procedures&#xD;
&#xD;
        -  Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is&#xD;
           approved in the country where the study is being conducted. JAK2 inhibitors are to be&#xD;
           used according to their respective label and as prescribed as part of the subject's&#xD;
           standard-of-care therapy as prescribed by their physician prior to study entry.&#xD;
&#xD;
        -  Best supportive care (BSC) includes, but is not limited to, treatment with transfusions&#xD;
           (eg, RBC, platelet, whole blood), ICTs, antibiotic, antiviral and/or antifungal therapy,&#xD;
           and nutritional support as needed.&#xD;
&#xD;
        -  Granulocyte colony-stimulating factors (ie, G-CSF, granulocyte macrophage&#xD;
           colony-stimulating factor [GM-CSF]) are allowed only in cases of neutropenic fever or as&#xD;
           clinically indicated per product label.&#xD;
&#xD;
        -  Prophylactic antithrombotic therapy is permitted.&#xD;
&#xD;
        -  Thrombopoietin and platelet transfusions are permitted.&#xD;
&#xD;
        -  Treatment with systemic corticosteroids is permitted for nonhematological conditions&#xD;
           providing the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone&#xD;
           during the study.&#xD;
&#xD;
        -  Administration of attenuated vaccines (eg, influenza vaccine) is allowed if clinically&#xD;
           indicated per Investigator discretion.&#xD;
&#xD;
        -  Iron chelation therapy (ICT) is to be used according to the product label. If the label&#xD;
           permits, the ICT dose should be stable during at least the first 24 weeks of IP.&#xD;
           Initiation of ICT while within the first 24 weeks of IP should be clinically indicated&#xD;
           to treat an AE.&#xD;
&#xD;
      Prohibited Concomitant Medications&#xD;
&#xD;
      The following concomitant medications are specifically excluded during the course of the&#xD;
      study:&#xD;
&#xD;
        -  Cytotoxic, chemotherapeutic, targeted, or investigational agents/therapies (excluding&#xD;
           JAK2 inhibitor therapy)&#xD;
&#xD;
        -  Azacitidine, decitabine, or other hypomethylating agents&#xD;
&#xD;
        -  Lenalidomide, thalidomide, and pomalidomide&#xD;
&#xD;
        -  Erythropoietin stimulating agents (ESAs) and other RBC hematopoietic growth factors (eg,&#xD;
           IL-3)&#xD;
&#xD;
        -  Hydroxyurea or other alkylating agents&#xD;
&#xD;
        -  Androgens (unless given to treat hypogonadism)&#xD;
&#xD;
        -  Oral retinoids (topical retinoids are permitted)&#xD;
&#xD;
        -  Arsenic trioxide&#xD;
&#xD;
        -  Interferon&#xD;
&#xD;
        -  Anagrelide&#xD;
&#xD;
        -  Systemic corticosteroids at a dose equivalent to &gt; 10 mg prednisone&#xD;
&#xD;
        -  Investigational products for the treatment of MPN-associated MF&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">February 11, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Red blood cell-transfusion independence (RBC-TI) ≥ 12 weeks (RBC-TI 12)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Proportion of subjects who become RBC-transfusion free over any consecutive 12-week period starting within the first 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red blood cell-transfusion independence ≥ 16 weeks (RBC-TI 16)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Proportion of subjects who become RBC-transfusion free over any consecutive 16-week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Red blood cell-transfusion independence (RBC-TI 12)</measure>
    <time_frame>Up to end of treatment, approximately 3 years</time_frame>
    <description>Maximum duration of RBC-TI response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of transfusion burden by ≥ 50% and by ≥ 4 units/12 weeks from baseline over any consecutive 12-week period</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Proportion of subjects who reduce their transfusion burden by ≥ 50% and by ≥ 4 units/12 weeks from baseline over any consecutive 12-week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of reduction in transfusion burden</measure>
    <time_frame>Up to end of treatment, approximately 3 years</time_frame>
    <description>Maximum duration of when RBC-transfusion dependent subjects who reduce their transfusion burden by ≥ 50% and by ≥ 4 units/12 weeks from baseline over any consecutive 12 week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell-transfusion independence ≥ 12 weeks in the treatment period (RBC-TI 12/TP)</measure>
    <time_frame>Up to end of treatment, approximately 3 years</time_frame>
    <description>Proportion of subjects who become RBC-transfusion free over any consecutive 12-week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell-transfusion independence ≥ 16 weeks in the treatment period (RBC-TI 16/TP)</measure>
    <time_frame>Up to end of treatment, approximately 3 years</time_frame>
    <description>Proportion of subjects who become RBC-transfusion free over any consecutive 16-week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RBC transfusion burden</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Mean change in transfusion burden (RBC units) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of RBC-transfusion independence</measure>
    <time_frame>Up to end of treatment, approximately 3 years</time_frame>
    <description>Cumulative response duration for subjects achieving multiple episodes of RBC-TI 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hgb increase ≥ 1 g/dL from baseline over any consecutive 12-week period in absence of RBC transfusions</measure>
    <time_frame>Up to end of treatment, approximately 3 years</time_frame>
    <description>Proportion of subjects achieving a mean Hgb increase ≥ 1 g/dL from baseline over any consecutive 12-week period in absence of RBC transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum ferritin from baseline</measure>
    <time_frame>Up to end of treatment, approximately 3 years</time_frame>
    <description>Change in serum ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>From screening up to 42 days post last dose</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transformation to blast phase: Number of subjects who transform into AML</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>AML = acute myeloid leukemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Antidrug antibodies (ADA)</measure>
    <time_frame>From randomization and up to including 48 weeks post first dose</time_frame>
    <description>Will be collected for assessment of anti-drug antibodies (ADA) against Luspatercept in serum in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area Under the Concentration-Time Curve (AUC)</measure>
    <time_frame>From randomization and up to including 48 weeks post first dose</time_frame>
    <description>Measures of luspatercept exposure area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum plasma concentration of drug (Cmax)</measure>
    <time_frame>From randomization and up to including 48 weeks post first dose</time_frame>
    <description>Maximum plasma concentration of drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">309</enrollment>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Myelofibrosis</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Post-Polycythemia Vera Myelofibrosis</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Experimental Arm: Luspatercept (ACE-536)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Luspatercept will be given to participants via subcutaneous injection (administered on Day 1 of each 21-day treatment cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo starting dose with volume equivalent to experimental arm subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-536</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>Experimental Arm: Luspatercept (ACE-536)</arm_group_label>
    <other_name>Luspatercept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>Control Arm: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must satisfy the following criteria to be randomized in the study:&#xD;
&#xD;
          1. Subject is ≥18 years of age at the time of signing the ICF.&#xD;
&#xD;
          2. Subject has a diagnosis of PMF according to the 2016 World Health Organization (WHO)&#xD;
             criteria or diagnosis of post-ET or post-PV MF according to the IWG-MRT 2007 criteria&#xD;
             , confirmed by the most recent local pathology report.&#xD;
&#xD;
          3. Subject is requiring RBC transfusions as defined as:&#xD;
&#xD;
             a. Average RBC-transfusion frequency: 4 to 12 RBC units/12 weeks immediately up to&#xD;
             randomization. There must be no interval &gt; 6 weeks (42 days) without ≥ 1 RBC&#xD;
             transfusion.&#xD;
&#xD;
             b. RBC transfusions are scored in determining eligibility when given for treatment of:&#xD;
&#xD;
             - Symptomatic (ie, fatigue or shortness of breath) anemia with a pretransfusion Hgb ≤&#xD;
             9.5 g/dL or&#xD;
&#xD;
               -  Asymptomatic anemia with a pretransfusion Hgb ≤ 7 g/dL c. RBC transfusions given&#xD;
                  for worsening of anemia due to bleeding or infections are not scored in&#xD;
                  determining eligibility.&#xD;
&#xD;
          4. Subjects on continuous (eg, absent of dose interruptions lasting ≥ 2 consecutive&#xD;
             weeks) JAK2 inhibitor therapy as approved in the country of the study site for the&#xD;
             treatment for MPN-associated MF as part of their standard-of-care therapy for at least&#xD;
             32 weeks, on stable daily dose for at least 16 weeks immediately up to the date of&#xD;
             randomization and anticipated to be on a stable daily dose of that JAK2 inhibitor for&#xD;
             at least 24 weeks after randomization.&#xD;
&#xD;
          5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2.&#xD;
&#xD;
          6. A female of childbearing potential (FCBP) for this study is defined as a female who:&#xD;
             1) has achieved menarche at some point, 2) has not undergone a hysterectomy or&#xD;
             bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea&#xD;
             following cancer therapy does not rule out childbearing potential) for at least 24&#xD;
             consecutive months (eg, has had menses at any time in the preceding 24 consecutive&#xD;
             months). Females of childbearing potential (FCBP)participating in the study must:&#xD;
&#xD;
             a. Have 2 negative pregnancy tests as verified by the Investigator prior to starting&#xD;
             study therapy. She must agree to ongoing pregnancy testing during the study, and after&#xD;
             end of IP. This applies even if the subject practices true abstinence* from&#xD;
             heterosexual contact.&#xD;
&#xD;
             b. Either commit to true abstinence* from heterosexual contact (which must be reviewed&#xD;
             on a monthly basis and source documented) or agree to use, and be able to comply with,&#xD;
             effective contraception** without interruption, 28 days prior to starting IP, during&#xD;
             the study therapy (including dose interruptions), and for 12 weeks (approximately 5&#xD;
             times the mean terminal half-life of IP based on multiple-dose PK data) after&#xD;
             discontinuation of study therapy.&#xD;
&#xD;
          7. Male subjects must: Practice true abstinence* (which must be reviewed on a monthly&#xD;
             basis) or agree to use a condom during sexual contact with a pregnant female or a&#xD;
             female of childbearing potential** while participating in the study, during dose&#xD;
             interruptions and for at least 12 weeks (approximately 5 times the mean terminal&#xD;
             half-life of IP based on multiple-dose PK data) following IP discontinuation, even if&#xD;
             he has undergone a successful vasectomy.&#xD;
&#xD;
             * True abstinence is acceptable when it is in line with the preferred and usual&#xD;
             lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation,&#xD;
             symptothermal, postovulation methods) and withdrawal are not acceptable methods of&#xD;
             contraception.]&#xD;
&#xD;
             ** Agreement to use highly effective methods of contraception that alone or in&#xD;
             combination result in a failure rate of a Pearl index of less than 1% per year when&#xD;
             used consistently and correctly throughout the course of the study. Such methods&#xD;
             include: Combined (estrogen and progestogen containing) hormonal contraception: Oral,&#xD;
             Intravaginal, Transdermal; Progestogen-only hormonal contraception associated with&#xD;
             inhibition of ovulation: Oral, Injectable hormonal contraception, Implantable hormonal&#xD;
             contraception; Placement of an intrauterine device (IUD); Placement of an intrauterine&#xD;
             hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner;&#xD;
             Sexual Abstinence.&#xD;
&#xD;
          8. Subject must understand and voluntarily sign an ICF prior to any study-related&#xD;
             assessments/procedures being conducted.&#xD;
&#xD;
          9. Subject is willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements including the use of the electronic patient reported outcomes device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a subject from randomization:&#xD;
&#xD;
          1. Subject with anemia from cause other than MPN-associated MForJAK2 inhibitor therapy&#xD;
             (eg, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic&#xD;
             anemia, infection, or any type of known clinically significant bleeding or&#xD;
             sequestration).&#xD;
&#xD;
          2. Subject use of hydroxyurea, immunomodulatory compounds such as pomalidomide,&#xD;
             thalidomide, ESAs, androgenic steroids or other drugs with potential effects on&#xD;
             hematopoiesis ≤ 8 weeks immediately up to the date of randomization.&#xD;
&#xD;
               1. Systemic corticosteroids are permitted for nonhematological conditions providing&#xD;
                  the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone for the&#xD;
                  4 weeks immediately up to randomization.&#xD;
&#xD;
               2. Iron chelation therapy (ICT) is permitted providing the subject is receiving a&#xD;
                  stable dose for the 8 weeks immediately up to randomization.&#xD;
&#xD;
          3. Subject with any of the following laboratory abnormalities at screening:&#xD;
&#xD;
               1. Neutrophils: &lt; 1 x 109/L&#xD;
&#xD;
               2. White blood count (WBC): &gt; 100 x 109/L&#xD;
&#xD;
               3. Platelets: the lowest allowable level as approved for the concomitant JAK2&#xD;
                  inhibitor but not &lt; 25 x 109/L or &gt; 1000 x 109/L&#xD;
&#xD;
               4. Peripheral blood myeloblasts:&gt; 5%&#xD;
&#xD;
               5. Estimated glomerular filtration rate:&lt; 40 mL/min/1.73 m2 (via the 4-variable&#xD;
                  modification of diet in renal disease [MDRD] formula) or nephrotic subjects (eg,&#xD;
                  urine albumin-to-creatinine ratio &gt; 3500 mg/g)&#xD;
&#xD;
               6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):&gt; 3.0 x upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               7. Direct bilirubin: ≥ 2 x ULN&#xD;
&#xD;
                    -  Higher levels are acceptable if these can be attributed to active red blood&#xD;
                       cell precursor destruction within the bone marrow (eg, ineffective&#xD;
                       erythropoiesis)&#xD;
&#xD;
          4. Subject with uncontrolled hypertension, defined as repeated elevations of systolic&#xD;
             blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, that is not resolved&#xD;
             at the time of randomization.&#xD;
&#xD;
          5. Subject with prior history of malignancies, other than disease under study, unless the&#xD;
             subject has been free of the disease for ≥ 3 years. However, subject with the&#xD;
             following history/concurrent conditions is allowed:&#xD;
&#xD;
               1. Basal or squamous cell carcinoma of the skin&#xD;
&#xD;
               2. Carcinoma in situ of the cervix&#xD;
&#xD;
               3. Carcinoma in situ of the breast&#xD;
&#xD;
               4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,&#xD;
                  nodes, metastasis [TNM] clinical staging system)&#xD;
&#xD;
          6. Subject with prior hematopoietic cell transplant or subject anticipated to receive a&#xD;
             hematopoietic cell transplant during the 24 weeks from the date of randomization. 7.&#xD;
             Subject with stroke, myocardial infarction, deep venous thrombosis, pulmonary or&#xD;
             arterial embolism within 6 months immediately up to the date of randomization.&#xD;
&#xD;
        8. Subject with major surgery within 2 months up to the date of randomization. Subject must&#xD;
        have completely recovered from any previous surgery immediately up to the date of&#xD;
        randomization.&#xD;
&#xD;
        9. Subject with a major bleeding event (defined as symptomatic bleeding in a critical area&#xD;
        or organ and/or bleeding causing a decrease in Hgb of ≥ 2 g/dL or leading to transfusion of&#xD;
        ≥ 2 units of packed red cells) in the last 6 months prior to the date of randomization.&#xD;
&#xD;
        10.Subject with inadequately controlled heart disease and/or have a known left ventricular&#xD;
        ejection fraction &lt; 35%.&#xD;
&#xD;
        11.Subject with uncontrolled systemic fungal, bacterial, or viral infection (defined as&#xD;
        ongoing signs/symptoms related to the infection without improvement despite appropriate&#xD;
        antibiotics, antiviral therapy, and/or other treatment).&#xD;
&#xD;
        12.Subject with known human immunodeficiency virus (HIV), evidence of active Hepatitis B&#xD;
        (HepB) as demonstrated by the presence of Hepatitis B surface antigen (HBsAg) and/or&#xD;
        positive for Hepatitis B virus DNA (HBVDNA-positive), and/or evidence of active Hepatitis C&#xD;
        (HepC) as demonstrated by a positive Hepatitis C virus RNA (HCV-RNA) test of sufficient&#xD;
        sensitivity.&#xD;
&#xD;
        13.Subject with prior therapy of luspatercept or sotatercept. 14.Subject with history of&#xD;
        severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or&#xD;
        excipients in the investigational product.&#xD;
&#xD;
        15.Pregnant or breastfeeding females. 16.Subject participation in any other clinical&#xD;
        protocol or investigational trial that involves use of experimental therapy (including&#xD;
        investigational agents) and/or therapeutic devices within 30 days or for investigational&#xD;
        agents within five half-lives, whichever comes later, immediately up to the date of&#xD;
        randomization.&#xD;
&#xD;
        17.Subject with any significant medical condition, laboratory abnormality, psychiatric&#xD;
        illness, or is considered vulnerable by local regulations (eg, imprisoned or&#xD;
        institutionalized) that would prevent the subject from participating in the study or places&#xD;
        the subject at unacceptable risk if he/she were to participate in the study. 18.Subject&#xD;
        with any condition or concomitant medication that confounds the ability to interpret data&#xD;
        from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torsten Gerike, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35924</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-6094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College - New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CTRC at The UT Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-4417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz, I Interne Abteilung</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien, Universitatsklinik fur Dermatologie. Abteilung fur Immundermatologie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer - La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires UCL de Mont-Godine</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2S2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 6B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis - Jewish Genl</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke-Hospital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai 6th Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Tianjin</city>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna Fakultni Nemocnice v Praze</name>
      <address>
        <city>Prague 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital du Bocage</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille-Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Archet I</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau</name>
      <address>
        <city>Nimes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud Hopital Haut Leveque USN</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU La Miletrie</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICANS - Institut de cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unviversitatsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwab. Gmund</name>
      <address>
        <city>Baden-Warttemberg</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Duesseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Halle Saale</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>OncoResearch Lerchenfeld GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johannes Wiesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Alexandroupolis</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>08100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelismos General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11 527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Attikon university General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12464</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Rio Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgios Papanikolaou General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital the Chinese University of Hong Kong</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy University Hospital</name>
      <address>
        <city>Cork</city>
        <zip>D11 KXN4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Misercordiae Hospital</name>
      <address>
        <city>Dublin 7</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St James Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shamir Medical Center - Assaf Harofeh</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele - Ospedale Gaspare Rodolico</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli, Campania</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli</name>
      <address>
        <city>Reggio Di Calabria</city>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant Andrea</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S Eugenio</name>
      <address>
        <city>Roma</city>
        <zip>144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S Maria di Terni</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi dell'Insubria - Ospedale di Circolo e Fondazione Macchi - Varese</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aomori Prefectural Central Hospital</name>
      <address>
        <city>Aomori</city>
        <zip>030-8553</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Yamanashi Hospital</name>
      <address>
        <city>Chuo</city>
        <zip>409-3898</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara City, Kanagawa</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kameda General Hospital</name>
      <address>
        <city>Kamogawa</city>
        <zip>296-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Maebashi</city>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miyazaki Hospital</name>
      <address>
        <city>Miyazaki</city>
        <zip>889-1692</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Japanese Red Cross Nagasaki Genbaku Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka-Sayama</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapporo Hokuyu Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>003-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Shinagawa-ku, Tokyo</city>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Shinjuku City</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjyuku-ku</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-Gun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul - Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Lodzi</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ALVAMED</name>
      <address>
        <city>Poznan</city>
        <zip>61-696</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Szpital im. dra Alfreda Sokolowskiego</name>
      <address>
        <city>Walbrzych</city>
        <zip>58-309</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moscow State Healthcare Institution City clinical hospital n.a. S.P.Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov</name>
      <address>
        <city>St Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>First St Petersburg State Medical University na IP Pavlov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol ICO Badalona</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgenes de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr. Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>7120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitario de Salamanca - Hospital Clinico</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>United Lincolnshire Hospitals NHS Trust</name>
      <address>
        <city>Boston</city>
        <zip>PE21 9QS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's Cancer Centre</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Churchhill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LI</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Luspatercept</keyword>
  <keyword>ACE-536</keyword>
  <keyword>Myeloproliferative Neoplasm</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>JAK2</keyword>
  <keyword>Red blood cell transfusion</keyword>
  <keyword>Post-ET MF</keyword>
  <keyword>Post-PV MF</keyword>
  <keyword>Reblozyl</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Luspatercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

